地拉罗司可治疗什么病症呢？

The iron chelator product (Deferasirox) developed by the Swiss pharmaceutical company Novartis is the first oral iron-removing agent approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old. So, what conditions can Deferasirox treat?

Indications of Deferasirox:

1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop symptoms of chronic iron overload when serum ferritin continues to be >1000 L. At this time, iron chelation therapy should be started. 

2. Patients receiving ASCT treatment can also be given iron chelator treatment when iron overload occurs;

3. It can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

Deferasirox dispersible tablets should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole.

Deferasirox dispersible tablets should not be taken together with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet.

Completely dissolve Deferasirox tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining drug must be added to a small amount of water, apple juice or orange juice and mixed well before taking it.

Deferasirox is not recommended to be dissolved in carbonated drinks or milk because it can cause foaming and slow dispersion.

In order to ensure that the efficacy of Deferasirox is better exerted, combination with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine should be avoided. Do not administer concurrently with aluminum-containing antacids. Not to be combined with other iron chelation treatments. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold deferasirox at least 5 days before performing gallium-67 imaging.

The above is the content of the indications of Deferasirox, I hope it can help you!